- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04936568
Palliative Care Referral System (PCRS) for Cancer Patients With Advanced Disease (PCRSS)
February 28, 2023 updated by: Augusto Caraceni, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Implementation of a Standardized Palliative Care Referral System (PCRS) for Cancer Patients With Advanced Disease: Impact on Patient and Caregiver Satisfaction With Care and Use of Health Care Resources.
Early palliative care (EPC) in the clinical pathway of advanced cancer patients improves symptom control, quality of life and has a positive impact on overall quality of care.
EPC contributes to realistic and attainable goals of treatment, facilitating patient choices, favouring adequate communication with patients and families and assessing patient values and preferences with regard to advance care planning.
EPC is likely to promote a more appropriate use of health care resources and less aggressive cancer treatment in the last weeks of life.
At present standardised criteria for appropriate referral for EPC in oncology outpatients setting are lacking.
Therefore the aim of this project is to identify referral criteria and procedures to implement appropriate EPC for advanced patients (the Palliative Care Referral System) and test them in a pre-post experimental design evaluating their impact on quality of care and on the use of healthcare resources.
A quasi-experimental, longitudinal, pretest-posttest study will be carried out.
Two different cohorts of 150 advanced cancer patients each will be enrolled before (pretest) and after (posttest) the introduction of the PCRS in outpatient clinics of a Comprehensive Cancer Centre.
Eligible patients will undergo patient-reported outcome measure (PROMs) evaluation at baseline and then monthly for at least 6 months from enrollment or till death.
Use health care resources and quality of care indicators will be collected monthly by a dedicated research nurse.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
As above.
Study Type
Interventional
Enrollment (Anticipated)
300
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milan, Italy, 20133
- Recruiting
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age >18 years;
- recent diagnosis of inoperable locally advanced and/or metastatic cancer not eligible to anticancer treatment with curative intent;
Exclusion Criteria:
- cognitive impairment that would prevent self-assessments
- current palliative care treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: control
standard oncology care
|
|
Experimental: intervention
standardized referral to outpatient palliative care by oncologists
|
Implementation of a system to help oncologists to identify criteria for referring patients to specialized outpatient palliative care (Palliative Care Referral System - PCRS)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
patient reported experience
Time Frame: through study completion, up to 6 months
|
patient satisfaction with care, measured with the FAMCARE-P13
|
through study completion, up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health related quality of life
Time Frame: through study completion, up to 6 months
|
European Organisation for Research and Treatment of Cancer - Quality of Life -Palliative Care questionnaire (Eortc QLQC15-PAL)
|
through study completion, up to 6 months
|
caregiver experience of care
Time Frame: through study completion, up to 6 months
|
Family Care Satisfaction scale (FAMCARE)
|
through study completion, up to 6 months
|
Activation of a Palliative Care service
Time Frame: through study completion, up to 6 months
|
Number of regular outpatient Palliative Care visits
|
through study completion, up to 6 months
|
Multidisciplinary team visits
Time Frame: through study completion, up to 6 months
|
Number of multidisciplinary team visits (Oncology and Palliative Care)
|
through study completion, up to 6 months
|
Hospitalization
Time Frame: through study completion, up to 6 months
|
Number of hospitalizations
|
through study completion, up to 6 months
|
Emergency department accesses
Time Frame: through study completion, up to 6 months
|
Number of accesses in Emergency departement
|
through study completion, up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 14, 2021
Primary Completion (Anticipated)
July 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
June 8, 2021
First Submitted That Met QC Criteria
June 22, 2021
First Posted (Actual)
June 23, 2021
Study Record Updates
Last Update Posted (Actual)
March 1, 2023
Last Update Submitted That Met QC Criteria
February 28, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 201/19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
not planned
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
AstraZenecaTerminatedCancer | Advanced Solid Tumors | Advanced Solid MalignanciesUnited States
-
Suzhou Transcenta Therapeutics Co., Ltd.Bristol-Myers SquibbRecruiting
Clinical Trials on Palliative Care Referral System - PCRS
-
University of RochesterAmerican Academy of NeurologyCompletedParkinson DiseaseUnited States
-
University Health Network, TorontoCanadian Cancer Society (CCS)Active, not recruiting
-
Centre Leon BerardNot yet recruiting
-
University of AarhusAarhus University Hospital; Research Unit for General Practice, Aarhus UniversityWithdrawn
-
Allina Health SystemCompleted
-
Massachusetts General HospitalPatient-Centered Outcomes Research InstituteRecruitingHigh Risk Acute Myeloid Leukemia | Relapsed Adult AML | Primary Refractory Acute Myeloid LeukemiaUnited States
-
Duke UniversityNational Institute of Nursing Research (NINR)CompletedHeart Diseases | Cardiovascular Diseases | Heart FailureUnited States
-
Massachusetts General HospitalAmerican Society of Clinical OncologyCompletedNon-small Cell Lung CancerUnited States
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong KongCompletedPalliative Care | Renal Failure, End-stageHong Kong
-
University of Colorado, DenverNational Institute of Nursing Research (NINR); University of California, San...CompletedParkinson Disease | Alzheimer Disease | Lewy Body Disease | Parkinsonism | Supranuclear Palsy, Progressive | Parkinsonism Vascular | Multiple System Atrophy | Corticobasal Degeneration | Frontotemporal Dementia | Primary Progressive Aphasia | Vascular DementiaUnited States